Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616185 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
NCT02616185 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 91 participants.
The verdict
NCT02616185, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
Study Summary
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.
Interventions
- BIOLOGICAL Tremelimumab
- BIOLOGICAL PF-06755992
- BIOLOGICAL PF-06755990
- DEVICE TDS-IM Electroporation Device
- BIOLOGICAL PF-06801591
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2015-12-30 |
| Est. Completion | 2021-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02616185
The ClinicalTrials.gov registry entry for NCT02616185 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tremelimumab is the first listed.
NCT02616185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02616185 about?
NCT02616185 is a clinical study titled "A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)". The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.
What is the current status of trial NCT02616185?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2015-12-30. Estimated completion is 2021-02-23.
What interventions are being tested in trial NCT02616185?
The interventions under investigation include: Tremelimumab (BIOLOGICAL), PF-06755992 (BIOLOGICAL), PF-06755990 (BIOLOGICAL), TDS-IM Electroporation Device (DEVICE), PF-06801591 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02616185?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.